Carlson B A, Dubay M M, Sausville E A, Brizuela L, Worland P J
Laboratory of Biological Chemistry, Division of Basic Science, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
Cancer Res. 1996 Jul 1;56(13):2973-8.
Flavopiridol (L86-8275), a N-methylpiperidinyl, chlorophenyl flavone, can inhibit cell cycle progression in either G1 or G2 and is a potent cyclin-dependent kinase (CDK) 1 inhibitor. In this study, we used MCF-7 breast carcinoma cells that are wild type for p53 and pRb positive and contain CDK4-cyclin D1 and MDA-MB-468 breast carcinoma cells that are mutant p53, pRb negative, and lack CDK4-cyclin D1 to investigate the G1 arrest produced by Flavopiridol. Recombinant CDK4-cyclin D1 was inhibited potently by Flavopiridol (Kiapp, 65 nM), competitive with respect to ATP. Surprisingly, CDK4 immunoprecipitates derived from Flavopiridol-treated MCF-7 cells (3 h, 300 nM Flavonolpiridol) had an approximately 3-fold increased kinase activity compared with untreated cells. Cyclin D and CDK4 levels were not different at 3 hr, but cyclin D levels and CDK4 kinase activity decreased thereafter. The phosphorylation state of pRb was shifted from hypercoincident to hypocoincident with the development of G1 arrest. Asynchronous MDA-MB-468 cells were inhibited in cell cycle progression at both G1 and G2 by Flavopiridol. Flavopiridol inhibited the in vitro kinase activity of CDK2 using an immune complex kinase assay (IC50, 100 nM at 400 microM ATP). Immunoprecipitated CDK2 kinase activity from either MCF-7 or MDA-MB-468 cells exposed to Flavopiridol (300 nM) for increasing time showed an initial increased activity (approximately 1.5-fold at 3 h) compared with untreated cells, followed by a loss of kinase activity to immeasurable levels by 24 h. This increased immunoprecipitated kinase activity was dependent on the Flavopiridol concentration added to intact cells and was associated with a reduction of CDK2 tyrosine phosphorylation. Cyclin E and A levels were not altered to the same extent as cyclin D, and neither CDK4 nor CDK2 levels were changed in response to Flavopiridol. Inhibition of the CDK4 and/or CDK2 kinase activity by Flavopiridol can therefore account for the G1 arrest observed after exposure to Flavopiridol.
黄酮哌啶醇(L86 - 8275),一种N - 甲基哌啶基氯苯基黄酮,可在G1期或G2期抑制细胞周期进程,是一种有效的细胞周期蛋白依赖性激酶(CDK)1抑制剂。在本研究中,我们使用p53野生型、pRb阳性且含有CDK4 - 细胞周期蛋白D1的MCF - 7乳腺癌细胞,以及p53突变、pRb阴性且缺乏CDK4 - 细胞周期蛋白D1的MDA - MB - 468乳腺癌细胞,来研究黄酮哌啶醇产生的G1期阻滞。黄酮哌啶醇能有效抑制重组CDK4 - 细胞周期蛋白D1(Kiapp,65 nM),对ATP具有竞争性。令人惊讶的是,与未处理细胞相比,从用黄酮哌啶醇处理的MCF - 7细胞(3小时,300 nM黄酮哌啶醇)中免疫沉淀得到的CDK4具有约3倍的激酶活性增加。3小时时细胞周期蛋白D和CDK4水平无差异,但此后细胞周期蛋白D水平和CDK4激酶活性下降。随着G1期阻滞的发展,pRb的磷酸化状态从高度一致转变为低度一致。异步MDA - MB - 468细胞在G1期和G2期的细胞周期进程均被黄酮哌啶醇抑制。使用免疫复合物激酶测定法,黄酮哌啶醇抑制了CDK2的体外激酶活性(在400 microM ATP时IC50为100 nM)。来自暴露于黄酮哌啶醇(300 nM)不同时间的MCF - 7或MDA - MB - 468细胞的免疫沉淀CDK2激酶活性,与未处理细胞相比,最初显示活性增加(3小时时约为1.5倍),随后到24小时激酶活性丧失至无法测量的水平。这种免疫沉淀激酶活性的增加取决于添加到完整细胞中的黄酮哌啶醇浓度,并与CDK2酪氨酸磷酸化的减少相关。细胞周期蛋白E和A水平的改变程度与细胞周期蛋白D不同,且CDK4和CDK2水平均未因黄酮哌啶醇而改变。因此,黄酮哌啶醇对CDK4和/或CDK2激酶活性的抑制可解释暴露于黄酮哌啶醇后观察到的G1期阻滞。